<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04472169</url>
  </required_header>
  <id_info>
    <org_study_id>2019_75</org_study_id>
    <secondary_id>2020-A00584-35</secondary_id>
    <nct_id>NCT04472169</nct_id>
  </id_info>
  <brief_title>UPLC-MS/MS Monitoring of Emicizumab Therapy</brief_title>
  <acronym>EMICARE</acronym>
  <official_title>Value of Emicizumab Monitoring With UPLC-MS/MS for Bleeding Risk Prediction in Severe Hemophilia A</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Groupement Interrégional de Recherche Clinique et d'Innovation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Emicizumab is a monoclonal bispecific antibody with a terminal half-life of 28 days which is
      now licensed in the treatment of severe haemophilia A with or without inhibitors. Some
      heterogeneity in residual emicizumab concentrations have been reported according to age, body
      mass index or drug therapeutic regimen. Some cases of neutralizing antidrug antibodies have
      been also reported. Whether monitoring emicizumab plasma concentration could predict the
      residual bleeding risk under emicizumab is unknown. As conventional coagulation assays are
      not adapted for emicizumab monitoring, this study aims to assess the value of monitoring
      residual emicizumab plasma concentration by UPLC-MS/MS in bleeding risk prediction.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve ROC of Residual plasma level of emicizumab</measure>
    <time_frame>At Week 5 (end of emicizumab loading period)</time_frame>
    <description>At least one clinically significant bleeding (defined as any bleeding treated with FVIII, rFVIIa or aPCC) from loading period completion (week 5) to the end of study, an average of 1 year</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab measured by UPLC-MS/MS</measure>
    <time_frame>At Week 5 (end of emicizumab loading period)</time_frame>
    <description>At least one hemarthrosis from loading period completion (week 5) to the end of study, an average of 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab measured by UPLC-MS/MS</measure>
    <time_frame>At each breakthrough bleeding until end of study</time_frame>
    <description>Post-traumatic or spontaneous nature of bleeding event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual plasma level of emicizumab (UPLC-MS/MS dosing)</measure>
    <time_frame>At Week 5 and at each breakthrough bleeding until end of study</time_frame>
    <description>Emicizumab FVIII-like activity (chromogenic FVIII BIOPHEN™assay system with emicizumab calibration)</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hemophilia A</condition>
  <arm_group>
    <arm_group_label>Severe haemophila A patients with or without inhibitors</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, poor-platelet plasma, whole blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients with severe hemophilia A will be included in the study on 2 french Hemophilia
        Treatement Centers (CHU Lille and CHU Caen)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult or child with Clinical diagnosis of severe hemophilia A (FVIII activity &lt; 1%)
             with or without inhibitor

          -  Clinical indication to emicizumab therapy

        Exclusion Criteria:

          -  Refusal to give informed consent

          -  acquired hemophilia A

          -  other inherited or acquired bleeding disorder

          -  bodyweight &lt; 10 kgs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Rauch, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>antoine.rauch@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <investigator>
      <last_name>Yohann Repesse, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Coeur-Poumon, Pôle d'Hématologie-Transfusion, CHU</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <phone>0320445962</phone>
    </contact>
    <investigator>
      <last_name>Antoine Rauch, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 10, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2020</study_first_posted>
  <last_update_submitted>July 10, 2020</last_update_submitted>
  <last_update_submitted_qc>July 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug monitoring</keyword>
  <keyword>Severe Hemophilia A</keyword>
  <keyword>Emicizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

